Total Payments
$136,390
2024 Payments
$8,871
Companies
9
Transactions
86
Payment Breakdown by Category
Consulting$96,998 (71.1%)
Travel$16,936 (12.4%)
Research$15,666 (11.5%)
Other$4,500 (3.3%)
Food & Beverage$1,872 (1.4%)
Education$263.00 (0.2%)
Gifts$154.45 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $96,998 | 23 | 71.1% |
| Travel and Lodging | $16,936 | 21 | 12.4% |
| Unspecified | $15,666 | 6 | 11.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,500 | 1 | 3.3% |
| Food and Beverage | $1,872 | 27 | 1.4% |
| Education | $263.00 | 5 | 0.2% |
| Gift | $154.45 | 3 | 0.1% |
Payments by Type
General
$120,724
80 transactions
Research
$15,666
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $43,255 | 12 | $0 (2020) |
| Alkermes, Inc. | $29,178 | 33 | $0 (2020) |
| Amgen Inc. | $17,875 | 8 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $15,666 | 6 | $0 (2024) |
| Merck Sharp & Dohme LLC | $9,516 | 3 | $0 (2023) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $9,091 | 9 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $8,508 | 11 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $2,700 | 3 | $0 (2023) |
| Biohaven Pharmaceutical Holding Company Ltd. | $600.00 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,871 | 4 | Teva Pharmaceuticals USA, Inc. ($8,871) |
| 2023 | $13,448 | 6 | Teva Pharmaceuticals USA, Inc. ($6,795) |
| 2022 | $1,049 | 2 | Biohaven Pharmaceutical Holding Company Ltd. ($600.00) |
| 2021 | $5,740 | 2 | Merck Sharp & Dohme Corporation ($5,115) |
| 2020 | $27,106 | 16 | Alkermes, Inc. ($10,800) |
| 2019 | $37,093 | 18 | Sunovion Pharmaceuticals Inc. ($31,085) |
| 2018 | $37,874 | 25 | Alkermes, Inc. ($17,544) |
| 2017 | $5,209 | 13 | Amgen Inc. ($4,375) |
All Payment Transactions
86 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,887.50 | Research |
| Study: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | ||||||
| 08/13/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $1,321.25 | Research |
| Study: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | ||||||
| 06/11/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $2,265.00 | Research |
| Study: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | ||||||
| 02/07/2024 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $3,397.50 | Research |
| Study: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | ||||||
| 12/29/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 11/07/2023 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $3,397.50 | Research |
| Study: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | ||||||
| 08/10/2023 | Teva Pharmaceuticals USA, Inc. | — | — | Cash or cash equivalent | $3,397.50 | Research |
| Study: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | ||||||
| 05/17/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 05/03/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 01/09/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,952.50 | General |
| 11/15/2022 | Biohaven Pharmaceutical Holding Company Ltd. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 09/19/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $448.62 | General |
| 12/13/2021 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $5,115.00 | General |
| 12/07/2021 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: Cardiology | ||||||
| 10/19/2020 | Alkermes, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,300.00 | General |
| 09/21/2020 | Alkermes, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| 09/15/2020 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $1,625.00 | General |
| Category: Cardiology | ||||||
| 04/15/2020 | Amgen Inc. | Repatha (Biological) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Cardiology | ||||||
| 02/28/2020 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $39.94 | General |
| 02/28/2020 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $36.31 | General |
| 02/28/2020 | Sunovion Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $34.00 | General |
| 02/28/2020 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $26.44 | General |
| 02/27/2020 | Sunovion Pharmaceuticals Inc. | — | Travel and Lodging | Cash or cash equivalent | $325.13 | General |
| 02/27/2020 | Sunovion Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $324.65 | General |
| 02/27/2020 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $119.05 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | Teva Pharmaceuticals USA, Inc. | $15,666 | 6 |
About Dr. John Newcomer, MD
Dr. John Newcomer, MD is a Psychiatry healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568480069.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Newcomer, MD has received a total of $136,390 in payments from pharmaceutical and medical device companies, with $8,871 received in 2024. These payments were reported across 86 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($96,998).
Ad
Practice Information
- Specialty Psychiatry
- Location Miami, FL
- Active Since 07/17/2006
- Last Updated 12/14/2011
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1568480069
Products in Payments
- 63402-304-07 (Drug) $18,975
- Repatha (Biological) $17,875
- 63402-304-30 (Drug) $12,110
- ABILIFY MYCITE (Drug) $8,437
- Aristada 441 mg (Drug) $834.49
- LATUDA (Drug) $310.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Miami
Dr. Marc Agronin, M.d, M.D
Psychiatry — Payments: $169,903
Psychiatry $169,903
Mr. Americo Padilla, Md, MD
Psychiatry — Payments: $152,249
Psychiatry $152,249
Dr. Carlos Danger, M.d, M.D
Psychiatry — Payments: $134,458
Psychiatry $134,458
Pedro Rodriguez, M.d, M.D
Psychiatry — Payments: $126,436
Psychiatry $126,436
Emelina Arocha, M.d, M.D
Psychiatry — Payments: $102,717
Psychiatry $102,717
Patricia Junquera, M.d, M.D
Psychiatry — Payments: $99,235
Psychiatry $99,235